Veru Inc (VERU)

$2.41 +0.04 (1.69%)
Market Cap 38.36M
Revenue (ttm) 0.00
Net Income (ttm) -22.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 34,000
Avg Vol 93,810
Day's Range N/A - N/A
Shares Out 16.05M
Stochastic %K 19%
Beta -1.50
Analysts Strong Sell
Price Target $25.00

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle l...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 509 6897
Address:
2916 North Miami Avenue, Suite 1000, Miami, United States
Ljkjr
Ljkjr Mar. 17 at 7:56 PM
$VERU 678 Dead Geese Found In East Hampton's Georgica Pond; Geese Found In Jamesport Positive For Avian Flu: DEC VERU’s Sabizabulin may help if it spreads to humans.
0 · Reply
gogogomm
gogogomm Mar. 16 at 7:04 PM
$VERU https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug The meeting minutes following the Type C meeting with the FDA are very positive. We plan to request FDA NDA approval soon. $NRXP 👍
1 · Reply
verusabiz
verusabiz Mar. 16 at 3:41 PM
$VERU If you need a good laugh when the share price is so crappy just read @biorich
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 14 at 12:55 PM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
Uneducated_gambler
Uneducated_gambler Mar. 12 at 11:48 AM
$VERU are you guys seeing this chart at zero?
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 1:04 PM
$VERU 08:37 on Mar. 09 2026 Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 9 at 12:32 PM
$VERU - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
0 · Reply
Spinderella
Spinderella Mar. 8 at 2:13 PM
$VERU https://clinicaltrials.gov/study/NCT07446998
0 · Reply
Bornjever
Bornjever Mar. 5 at 4:17 PM
$VERU I lost my ass on this so many times like no execution and hope you guys have better execution than I had.
0 · Reply
Traildog19
Traildog19 Mar. 5 at 1:19 PM
$VERU Cash balance increased to $33 million, expected to fund operations through the interim analysis of the phase 2B study. I smell a Cap raise.
0 · Reply
Latest News on VERU
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Mar 9, 2026, 8:30 AM EDT - 9 days ago

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Feb 11, 2026, 1:54 PM EST - 4 weeks ago

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Feb 4, 2026, 8:30 AM EST - 6 weeks ago

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Dec 17, 2025, 11:59 AM EST - 3 months ago

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Dec 17, 2025, 6:30 AM EST - 3 months ago

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Dec 10, 2025, 8:30 AM EST - 3 months ago

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present Two Abstracts at ObesityWeek 2025

Oct 31, 2025, 8:30 AM EDT - 4 months ago

Veru to Present Two Abstracts at ObesityWeek 2025

Veru Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 4 months ago

Veru Announces Proposed Public Offering

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Sep 23, 2025, 8:30 AM EDT - 6 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Veru Inc. (VERU) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 12:57 PM EDT - 7 months ago

Veru Inc. (VERU) Q3 2025 Earnings Call Transcript

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Aug 12, 2025, 6:30 AM EDT - 7 months ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Aug 11, 2025, 8:30 AM EDT - 7 months ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru Announces Reverse Stock Split

Aug 6, 2025, 8:30 AM EDT - 8 months ago

Veru Announces Reverse Stock Split

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jul 22, 2025, 8:30 AM EDT - 8 months ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Veru to Participate in the Virtual BTIG Obesity Health Forum

Jun 11, 2025, 8:30 AM EDT - 10 months ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 12:11 PM EDT - 10 months ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 28, 2025, 6:30 AM EDT - 10 months ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 26, 2025, 9:36 PM EDT - 10 months ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 12:42 PM EDT - 11 months ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:30 AM EDT - 11 months ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 9:25 AM EDT - 11 months ago

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 8, 2025, 6:30 AM EDT - 11 months ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

May 1, 2025, 8:30 AM EDT - 11 months ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 2:35 PM EST - 1 year ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Feb 13, 2025, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 10:34 AM EST - 1 year ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Jan 27, 2025, 6:30 AM EST - 1 year ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Dec 31, 2024, 8:30 AM EST - 1 year ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 26, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Nov 5, 2024, 8:30 AM EST - 1 year ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Veru to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 10, 2024, 8:39 AM EDT - 1 year ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

Veru Announces Steven B. Heymsfield M.D.

May 15, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Steven B. Heymsfield M.D.

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 14, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 8, 2024, 6:30 AM EDT - 2 years ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

Veru to Present at the GLP-1 Based Therapeutics Summit

May 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit

Ljkjr
Ljkjr Mar. 17 at 7:56 PM
$VERU 678 Dead Geese Found In East Hampton's Georgica Pond; Geese Found In Jamesport Positive For Avian Flu: DEC VERU’s Sabizabulin may help if it spreads to humans.
0 · Reply
gogogomm
gogogomm Mar. 16 at 7:04 PM
$VERU https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug The meeting minutes following the Type C meeting with the FDA are very positive. We plan to request FDA NDA approval soon. $NRXP 👍
1 · Reply
verusabiz
verusabiz Mar. 16 at 3:41 PM
$VERU If you need a good laugh when the share price is so crappy just read @biorich
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 14 at 12:55 PM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
Uneducated_gambler
Uneducated_gambler Mar. 12 at 11:48 AM
$VERU are you guys seeing this chart at zero?
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 1:04 PM
$VERU 08:37 on Mar. 09 2026 Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 9 at 12:32 PM
$VERU - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
0 · Reply
Spinderella
Spinderella Mar. 8 at 2:13 PM
$VERU https://clinicaltrials.gov/study/NCT07446998
0 · Reply
Bornjever
Bornjever Mar. 5 at 4:17 PM
$VERU I lost my ass on this so many times like no execution and hope you guys have better execution than I had.
0 · Reply
Traildog19
Traildog19 Mar. 5 at 1:19 PM
$VERU Cash balance increased to $33 million, expected to fund operations through the interim analysis of the phase 2B study. I smell a Cap raise.
0 · Reply
BioRich
BioRich Mar. 4 at 11:20 PM
$ALT What about this one that addresses $VERU's benefits for combating sarcopenia and musle loss?
0 · Reply
BioRich
BioRich Mar. 4 at 11:19 PM
$VERU Another one for Veru highlighting benefits to combat Sarcopenia and preventing muscle loss. Exciting times. Cheers!
1 · Reply
BioRich
BioRich Mar. 4 at 11:18 PM
$ALT Y'all going to check this out when $VERU highlights "Moving beyond BMI & Weight Loss Endpoints"? Looks like their combination with $NVO will be highlighted for it's muscle sparing capabilities. Would be nice to see data and claims that are defensible. Still waiting to see those comparator arm data for $ALT's LMP claims. Still believed to have shown better LMP in the Placebo arm than the Pemvi arm for $ALT. Cheers!
0 · Reply
BioRich
BioRich Mar. 4 at 11:11 PM
$VERU Love that Veru is leading this Workshop. What an opportunity to showcase the excellent profile of Veru's lean mass preservation combinations with $NVO.
0 · Reply
BioRich
BioRich Mar. 4 at 11:08 PM
$VERU Chairman, CEO, President of Veru highlighted as an expert speaker, along with the CSO.
1 · Reply
BioRich
BioRich Mar. 4 at 11:06 PM
$VERU Key Benefits of Attending the Summit is lead by reference to Veru:
0 · Reply
BioRich
BioRich Mar. 4 at 11:04 PM
$VERU Showcased at the 4th Annual Obesity & Weight Loss Drug Development Summit to: "Address the archaic reliance on BMI by exploring new FDA aligned clinical endpoints to learn to prioritize functional health and organ-specific metabolic recovery to secure regulatory approval and payer support in an increasingly crowded therapeutic landscape"
0 · Reply
BioRich
BioRich Mar. 4 at 10:56 PM
$VERU Haven't forgotten about you. Keep preserving that muscle and let's get a damn deal done! Here are some highlights from the upcoming "4th Obesity & Weight Loss Drug Development Summit." (July 14th-16) The summit specifically highlights $VERU in the same bullets as $NVO, $LLY and $RHHBY and calling them "Innovative Biotech" along with Canary and $MTSR For those interested, here's the link to the Summit and downloading the Agenda is free with this link: Summit Link: https://obesity-weight-loss-summit.com/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01 Event Guide Link: https://obesity-weight-loss-summit.com/full-event-guide/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01
1 · Reply
mrkymrk
mrkymrk Mar. 3 at 4:18 PM
$VERU Pfizer, Novo Nordisk and many others large pharmas have signed multi billion dollar deals with AI research companies to assist in formulating combinations for blockbuster drugs- particularly in obesity. Has VERU worked with any AI companies to simulate how enobosarm is evaluated in these models when combined with a GLP-1? If not, why? What are they waiting for? What is management doing behind the scenes other than continuing to charge the Plateau trial protocol over and over again. The latest call they are going back to Wegovy injectable form. They can’t make up their damn minds.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 3 at 1:54 PM
How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.
0 · Reply
Spinderella
Spinderella Mar. 2 at 3:04 PM
$VERU https://www.nbcnews.com/health/health-news/glp-1s-may-increase-risk-osteoporosis-gout-new-research-finds-rcna261024
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 12:43 AM
$VERU RSI: 76.25, MACD: 0.0275 Vol: 0.13, MA20: 2.45, MA50: 2.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply